Marksans Pharma Ltd's Q4FY25 Quarter Results
- 20 May 2025
Result Summary
- Marksans Pharma Ltd reported a 18.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16.0%.
- Its expenses for the quarter were down by 15.9% QoQ and up 21.2% YoY.
- The net profit decreased 26.1% QoQ and decreased 6.1% YoY.
- The earnings per share (EPS) of Marksans Pharma Ltd stood at 1.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 576.54 | 709.70 | 496.98 | -18.8% | 16.0% |
Total Expenses | 476.27 | 566.44 | 392.81 | -15.9% | 21.2% |
Profit Before Tax | 100.28 | 143.26 | 104.17 | -30.0% | -3.7% |
Tax | 22.63 | 38.19 | 21.46 | -40.7% | 5.5% |
Profit After Tax | 77.64 | 105.06 | 82.71 | -26.1% | -6.1% |
Earnings Per Share | 1.70 | 2.30 | 2.00 | -26.1% | -15.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Marksans Pharma Ltd is a pharmaceutical company that operates primarily in the healthcare sector, focusing on the development, manufacturing, and marketing of a wide range of pharmaceutical formulations. The company is known for its production of generic pharmaceuticals, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). Marksans Pharma has a global presence, catering to markets in the United States, Europe, and other countries. In recent years, the company has been actively working on expanding its product portfolio and enhancing its market reach through strategic partnerships and acquisitions. However, specific recent developments or strategic initiatives are not available from the provided data.
Revenue
In the fourth quarter of the fiscal year 2025, Marksans Pharma Ltd reported a total income of ₹576.54 crores. This represents a decrease of 18.8% compared to the previous quarter (Q3FY25), where total income was ₹709.70 crores. However, on a year-over-year basis, there was a 16.0% increase from the fourth quarter of the fiscal year 2024, which recorded a total income of ₹496.98 crores. The decline in total income from the previous quarter indicates a reduction in revenue generation, while the year-over-year growth highlights an overall improvement compared to the same period last year.
Profitability
Marksans Pharma Ltd's profitability metrics for Q4FY25 show a profit before tax of ₹100.28 crores, which is 30.0% lower than the ₹143.26 crores recorded in Q3FY25. Compared to Q4FY24, the profit before tax decreased by 3.7% from ₹104.17 crores. The tax expense for Q4FY25 was ₹22.63 crores, representing a 40.7% decrease from the previous quarter and a 5.5% increase year-over-year. The profit after tax for the quarter stood at ₹77.64 crores, down 26.1% from Q3FY25 and 6.1% compared to Q4FY24. These figures indicate a quarter-over-quarter decline in profitability but show a relatively stable performance year-over-year.
Operating Metrics
The company's total expenses for Q4FY25 amounted to ₹476.27 crores, reflecting a 15.9% decrease from the previous quarter's expenses of ₹566.44 crores. Year-over-year, total expenses increased by 21.2% from ₹392.81 crores in Q4FY24. The earnings per share (EPS) for Q4FY25 were ₹1.70, down 26.1% from the ₹2.30 reported in Q3FY25 and 15.0% lower than the ₹2.00 recorded in Q4FY24. The observed decrease in expenses quarter-over-quarter contrasts with the year-over-year increase, while the decline in EPS reflects reduced profitability per share compared to both the previous quarter and the same period last year.